At Centerline Biomedical, we work with Cleveland Clinic, National Institutes of Health, and other visionary organizations and venture capitalists to market the initial application of IOPS™ technology. Together, our advances from traditional endovascular procedures to the adoption of IOPS technology are helping to increase revenue opportunities, improve procedure outcomes, and lower radiation exposure.
Centerline Biomedical is a spin-off company from Cleveland Clinic, which maintains its ownership and presence on the Board of Directors while working in collaboration with Centerline Biomedical to advance our commitment to innovative IOPS technology.
Large Addressable Market.
We believe that the addressable market for the initial application of IOPS technology is substantial due to the continued growth of minimally invasive endovascular techniques that have already surpassed more invasive aortic procedures. As graft technology advances, traditional endovascular procedures are beginning to trend towards increased complexity and procedure time, increasing the need for technologies that enhance visualization and efficiencies.
The IOPS platform is applicable to many vascular procedures with the total addressable global market comprising approximately four million procedures annually. Additionally, IOPS also has the potential to address non-vascular procedures such as bronchoscopy, urology, and orthopedic surgery.
Centerline Biomedical is currently pursuing 510(k) clearance for IOPS.